CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer […]
CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal.
The Boston Business Journal’s Best Places to Work awards are designed to honor employers in the greater Boston area who go beyond the norm to foster a supportive, dynamic and meaningful work environment for their employees. Casma was honored in the “extra small” category, which covers companies with fewer than 50 employees.
“The strength of Casma’s science is embedded in the productivity of our team,” said Keith Dionne, Casma’s chief executive officer. “In the year since our launch, we have made it a top priority to ensure Casma is a nurturing, fun and invigorating place to work. This award is testament to those efforts, and we are delighted to be selected.”
The Boston Business Journal will recognize this year’s 79 honorees at an awards ceremony on June 19 at the World Trade Center in Boston. Honorees will also be featured in a special June 21 edition of the Boston Business Journal.
About Casma Therapeutics
Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy-lysosome system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications. Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.casmatx.com.
Ten Bridge Communications
Stephanie Simon, 617-581-9333
January 31, 2023Casma Therapeutics Announces CEO Transition
January 30, 2023Casma Therapeutics Announces new Nature Publication – “Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex”
In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex. A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state. Read full publication here